NasdaqGS:SVRABiotechs
Assessing Savara (SVRA) Valuation After Recent Share Price Weakness And Ongoing Losses
Savara stock in focus after recent performance and fundamentals
Savara (SVRA) has come into focus after recent share price weakness, including a 3.9% decline in the latest session and negative returns over the past week and month, despite strong multi year total returns.
The company has a market value of about US$1.3b, no reported revenue and a net loss of US$118.8 million. This puts the spotlight on its clinical stage pipeline and cash needs rather than current profitability.
See our latest...